Patents Assigned to Ocera Therapeutics, Inc.
-
Patent number: 11266620Abstract: Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate.Type: GrantFiled: November 20, 2017Date of Patent: March 8, 2022Assignees: UCL Business Ltd, Ocera Therapeutics, Inc.Inventors: Rajiv Jalan, Keith Anderson
-
Patent number: 11219611Abstract: Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.Type: GrantFiled: November 11, 2016Date of Patent: January 11, 2022Assignee: Ocera Therapeutics, Inc.Inventors: Laurene Wang, Stanley Bukofzer, Linda S. Grais
-
Patent number: 11161802Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: January 31, 2020Date of Patent: November 2, 2021Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 11066352Abstract: Embodiments of the present disclosure are related to improved processes for making L-ornithine phenylacetate without using any silver salts or forming any L-ornithine intermediate salts, such as a benzoate salt. The present processes may be used in the commercial scale manufacturing of L-ornithine phenylacetate with high yields and low impurities.Type: GrantFiled: May 7, 2018Date of Patent: July 20, 2021Assignee: Ocera Therapeutics, Inc.Inventors: Ludwig Pilsl, Georg Winkler, Frank Demartin, Vassil Elitzin
-
Patent number: 10835506Abstract: Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.Type: GrantFiled: August 16, 2016Date of Patent: November 17, 2020Assignee: Ocera Therapeutics, Inc.Inventors: Christopher F. Rose, Franck Rousseau
-
Patent number: 10550069Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: July 17, 2018Date of Patent: February 4, 2020Assignee: Ocera Therapeutics, Inc.Inventors: Keith E. Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 10258602Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: March 28, 2018Date of Patent: April 16, 2019Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
-
Patent number: 10173964Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: March 24, 2017Date of Patent: January 8, 2019Assignee: Ocera Therapeutics, Inc.Inventors: Keith E. Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 10040751Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as described in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: GrantFiled: October 1, 2015Date of Patent: August 7, 2018Assignee: Ocera Therapeutics, Inc.Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 9949949Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone sceretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: June 9, 2016Date of Patent: April 24, 2018Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme Fraser, Kamel Benakli, Eric Marsault, Mark L. Peterson
-
Patent number: 9604909Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: May 18, 2015Date of Patent: March 28, 2017Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 9493505Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: October 31, 2014Date of Patent: November 15, 2016Assignee: OCERA THERAPEUTICS, INC.Inventors: Eric Marsault, Carl St-Louis
-
Patent number: 9409945Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z— radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.Type: GrantFiled: April 27, 2015Date of Patent: August 9, 2016Assignee: Ocera Therapeutics, Inc.Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
-
Patent number: 9371297Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: February 8, 2008Date of Patent: June 21, 2016Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
-
Patent number: 9260379Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.Type: GrantFiled: January 21, 2015Date of Patent: February 16, 2016Assignee: Ocera Therapeutics, Inc.Inventors: Keith E. Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 9181298Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: GrantFiled: November 19, 2008Date of Patent: November 10, 2015Assignee: OCERA THERAPEUTICS, INC.Inventors: Eric Marsault, Kamel Benakli, Hamid Hoveyda, Mark Peterson, Sylvie Beaubien, Luc Oullet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 9133235Abstract: The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a minimum, possess adequate pharmacological properties to be useful as therapeutics for a range of disease indications. In particular, these compounds are useful for treatment and prevention of disorders characterized by hypermotilinemia and/or gastrointestinal hypermotility, including, but not limited to, diarrhea, cancer treatment-related diarrhea, cancer-induced diarrhea, chemotherapy-induced diarrhea, radiation enteritis, radiation-induced diarrhea, stress-induced diarrhea, chronic diarrhea, AIDS-related diarrhea, C.Type: GrantFiled: September 11, 2007Date of Patent: September 15, 2015Assignee: Ocera Therapeutics, Inc.Inventors: Eric Marsault, Graeme L. Fraser, Kamel Benakli, Carl St-Louis, Alain Rouillard, Helmut Thomas
-
Patent number: 9034925Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.Type: GrantFiled: June 9, 2014Date of Patent: May 19, 2015Assignee: Ocera Therapeutics, Inc.Inventors: Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
-
Patent number: 9018419Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z— radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.Type: GrantFiled: August 26, 2011Date of Patent: April 28, 2015Assignee: Ocera Therapeutics, Inc.Inventors: Pierre Deslongchamps, Yves Dory, Gilles Berthiaume, Luc Ouellet, Ruoxi Lan
-
Patent number: 8946473Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.Type: GrantFiled: October 5, 2011Date of Patent: February 3, 2015Assignee: Ocera Therapeutics, Inc.Inventors: Keith H. Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini